IFI44L

Summary

IFI44L (interferon induced protein 44 like, HGNC:17817) is a protein-coding gene on chromosome 1p31.1, encoding Interferon-induced protein 44-like (Q53G44). Type I interferon-stimulated gene (ISG) that plays a critical role in antiviral and antibacterial activity.

Predicted to be involved in immune response. Predicted to act upstream of or within cellular response to virus. Predicted to be located in cytoplasm.

Source: NCBI Gene 10964 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 93 total
• MANE Select transcript: NM_006820

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17817
Approved symbol	IFI44L
Name	interferon induced protein 44 like
Location	1p31.1
Locus type	gene with protein product
Status	Approved
Aliases	GS3686, TLDC5B
Ensembl gene	ENSG00000137959
Ensembl biotype	protein_coding
OMIM	613975
Entrez	10964

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 17 protein_coding, 6 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000370751, ENST00000450498, ENST00000452835, ENST00000459784, ENST00000462041, ENST00000474002, ENST00000476521, ENST00000476876, ENST00000486882, ENST00000494910, ENST00000679651, ENST00000679848, ENST00000679998, ENST00000680110, ENST00000680295, ENST00000680621, ENST00000681501, ENST00000681613, ENST00000869071, ENST00000869072, ENST00000869073, ENST00000869074, ENST00000971551, ENST00000971552, ENST00000971553, ENST00000971554

RefSeq mRNA: 6 — MANE Select: NM_006820 NM_001375646, NM_001375647, NM_001375648, NM_001375649, NM_001375650, NM_006820

CCDS: CCDS687, CCDS90985

Canonical transcript exons

ENST00000370751 — 9 exons

Exon	Start	End
ENSE00000932015	78627906	78628393
ENSE00001453557	78620448	78620571
ENSE00003467900	78641435	78641609
ENSE00003478692	78628951	78628999
ENSE00003529506	78635337	78635489
ENSE00003628397	78629720	78629915
ENSE00003645890	78641775	78646145
ENSE00003651549	78641021	78641121
ENSE00003662665	78637032	78637203

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 94.94.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.9343 / max 2025.9813, expressed in 1146 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
3670	22.2648	1140
3675	0.1963	83
3671	0.1441	58
3673	0.1423	54
3672	0.0951	37
3680	0.0916	47

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	94.94	gold quality
calcaneal tendon	UBERON:0003701	94.81	gold quality
trigeminal ganglion	UBERON:0001675	94.69	gold quality
mononuclear cell	CL:0000842	94.48	gold quality
leukocyte	CL:0000738	94.17	gold quality
pericardium	UBERON:0002407	93.82	gold quality
gall bladder	UBERON:0002110	91.84	gold quality
dorsal root ganglion	UBERON:0000044	90.32	gold quality
palpebral conjunctiva	UBERON:0001812	89.40	gold quality
penis	UBERON:0000989	88.60	gold quality
decidua	UBERON:0002450	87.25	gold quality
granulocyte	CL:0000094	86.26	gold quality
tendon	UBERON:0000043	85.80	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	84.44	gold quality
mucosa of stomach	UBERON:0001199	84.38	gold quality
corpus callosum	UBERON:0002336	84.35	gold quality
spinal cord	UBERON:0002240	84.16	gold quality
synovial joint	UBERON:0002217	83.92	gold quality
colonic epithelium	UBERON:0000397	83.91	gold quality
lymph node	UBERON:0000029	83.83	gold quality
apex of heart	UBERON:0002098	83.79	gold quality
spleen	UBERON:0002106	83.46	gold quality
vermiform appendix	UBERON:0001154	83.06	gold quality
right coronary artery	UBERON:0001625	82.50	gold quality
smooth muscle tissue	UBERON:0001135	82.22	gold quality
lateral globus pallidus	UBERON:0002476	81.74	gold quality
mucosa of paranasal sinus	UBERON:0005030	81.73	gold quality
parietal pleura	UBERON:0002400	81.58	gold quality
middle frontal gyrus	UBERON:0002702	81.07	gold quality
subcutaneous adipose tissue	UBERON:0002190	81.05	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-MTAB-11011	yes	1229.07
E-GEOD-76312	yes	1106.49
E-MTAB-7037	yes	1091.52
E-GEOD-93593	yes	728.67
E-GEOD-75140	yes	635.96
E-MTAB-8559	yes	577.51
E-GEOD-149689	yes	506.54
E-CURD-95	yes	337.84
E-ANND-3	yes	14.27
E-HCAD-13	yes	12.27
E-MTAB-6701	yes	9.26
E-GEOD-137537	yes	6.18
E-MTAB-6379	no	3279.69
E-MTAB-7052	no	902.23
E-CURD-53	no	639.35

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

174 targeting IFI44L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-8068	99.98	73.85	2376
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784

Literature-anchored findings (GeneRIF, showing 20)

• LMKB is the first protein identified to date that interacts with this portion of Ge-1. LMKB was expressed in human B and T lymphocyte cell lines; depletion of LMKB increased expression of IFI44L. (PMID:24755989)
• study reveals common CD46 and IFI44L SNPs associated with measles-specific humoral immunity, and highlights the importance of alternative splicing/virus cellular receptor isoform usage as a mechanism explaining inter-individual variation in immune response after live measles vaccine (PMID:28289848)
• Study demonstrated for the first time that IFI44L is a novel tumor suppressor to affect cancer stemness, metastasis, and drug resistance via regulating Met/Src signaling pathway in hepatocellular carcinoma and can be serve as an important prognostic marker. (PMID:29848298)
• miR-628-5p promotes growth and migration of osteosarcoma by targeting IFI44L. (PMID:31018104)
• A qPCR expression assay of IFI44L gene differentiates viral from bacterial infections in febrile children. (PMID:31409879)
• Associations Between IFI44L Gene Variants and Rates of Respiratory Tract Infections During Early Childhood. (PMID:32561935)
• Interferon-Induced Protein 44 and Interferon-Induced Protein 44-Like Restrict Replication of Respiratory Syncytial Virus. (PMID:32611756)
• IFI44L expression is regulated by IRF-1 and HIV-1. (PMID:33159419)
• Targeted Profiling of Immunological Genes during Norovirus Replication in Human Intestinal Enteroids. (PMID:33494515)
• Integrated weighted gene co-expression network analysis uncovers STAT1(signal transducer and activator of transcription 1) and IFI44L (interferon-induced protein 44-like) as key genes in pulmonary arterial hypertension. (PMID:34516357)
• IFI44L as a Forward Regulator Enhancing Host Antituberculosis Responses. (PMID:34722780)
• Identified Three Interferon Induced Proteins as Novel Biomarkers of Human Ischemic Cardiomyopathy. (PMID:34884921)
• The prognostic and clinical significance of IFI44L aberrant downregulation in patients with oral squamous cell carcinoma. (PMID:34903206)
• Differentially methylation of IFI44L gene promoter in Iranian patients with systemic lupus erythematosus and rheumatoid arthritis. (PMID:35059970)
• Identification of IFI44L as a new candidate molecular marker for systemic lupus erythematosus. (PMID:35349411)
• Epigenetic Regulation of IFI44L Expression in Monocytes Affects the Functions of Monocyte-Derived Dendritic Cells in Systemic Lupus Erythematosus. (PMID:35592687)
• IFI44L as a novel epigenetic silencing tumor suppressor promotes apoptosis through JAK/STAT1 pathway during lung carcinogenesis. (PMID:36584854)
• Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma. (PMID:36607476)
• Novel polymorphism of IFI44L associated with the susceptibility and clinical characteristics of systemic lupus erythematosus in a Chinese population. (PMID:36893516)
• ACSL4 upregulates IFI44 and IFI44L expression and promotes the proliferation and invasiveness of head and neck squamous cell carcinoma cells. (PMID:38989827)

Cross-species orthologs

23 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-197g15.9	ENSDARG00000002293
danio_rerio	si:ch211-197g15.5	ENSDARG00000009673
danio_rerio		ENSDARG00000010729
danio_rerio	ifi44b	ENSDARG00000015678
danio_rerio	ifi44a1	ENSDARG00000029720
danio_rerio	ifi44e	ENSDARG00000056501
danio_rerio	ifi44c2	ENSDARG00000060322
danio_rerio	ifi44f4	ENSDARG00000071355
danio_rerio	ifi44f1	ENSDARG00000071361
danio_rerio	ifi44a3	ENSDARG00000075791
danio_rerio		ENSDARG00000089661
danio_rerio	ifi44a5	ENSDARG00000092361
		ENSDARG00000092634
danio_rerio	ifi44c1	ENSDARG00000092883
danio_rerio	ifi44a8	ENSDARG00000093857
danio_rerio	ifi44f5	ENSDARG00000094747
danio_rerio	ifi44f3	ENSDARG00000094984
danio_rerio	ifi44a7	ENSDARG00000095309
danio_rerio	ifi44a6	ENSDARG00000095673
danio_rerio		ENSDARG00000107486
		ENSDARG00000111120
mus_musculus	Ifi44l	ENSMUSG00000039146
rattus_norvegicus	Ifi44l	ENSRNOG00000049994

Paralogs (1): IFI44 (ENSG00000137965)

Protein

Protein identifiers

Interferon-induced protein 44-like — Q53G44 (reviewed: Q53G44)

All UniProt accessions (6): Q53G44, A0A7P0T9R5, A0A7P0Z4K2, B4E019, C9JPJ0, H7C1K6

UniProt curated annotations — full annotation on UniProt →

Function. Type I interferon-stimulated gene (ISG) that plays a critical role in antiviral and antibacterial activity. During bacterial infection, promotes macrophage differentiation and facilitates inflammatory cytokine secretion. Plays a role in the control of respiratory syncytial virus/RSV infection, reducing the ability of the virus to replicate. Exhibits a low antiviral activity against hepatitis C virus. Also acts as a feedback regulator of IFN responses by negatively regulating IKBKB and IKBKE kinase activities through interaction with FKBP5.

Subunit / interactions. Interacts with FKBP5; this interaction modulates IKBKB and IKBKE kinase activities.

Subcellular location. Cytoplasm.

Induction. By type I interferons. By M.tuberculosis infection.

Similarity. Belongs to the IFI44 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q53G44-1	1	yes
Q53G44-2	2

RefSeq proteins (6): NP_001362575, NP_001362576, NP_001362577, NP_001362578, NP_001362579, NP_006811* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006571	TLDc_dom	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

UniProt features (13 total): sequence variant 7, sequence conflict 2, splice variant 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53G44-F1	86.22	0.48

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9909505	Modulation of host responses by IFN-stimulated genes

MSigDB gene sets: 328 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, LEE_SP4_THYMOCYTE, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, WALLACE_PROSTATE_CANCER_RACE_UP, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOZGIT_ESR1_TARGETS_DN, BROWNE_HCMV_INFECTION_12HR_UP, BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS, MISSIAGLIA_REGULATED_BY_METHYLATION_UP, MODULE_171, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP, RADAEVA_RESPONSE_TO_IFNA1_UP, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, GOBP_DEFENSE_RESPONSE_TO_VIRUS, DODD_NASOPHARYNGEAL_CARCINOMA_UP

GO Biological Process (2): immune response (GO:0006955), defense response to virus (GO:0051607)

GO Molecular Function (0):

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interferon Signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
immune system process	1
response to stimulus	1
defense response	1
response to virus	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1536 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IFI44L	RSAD2	Q8WXG1	909
IFI44L	IFI27	P40305	894
IFI44L	IFIT3	O14879	888
IFI44L	IFIT1	P09914	852
IFI44L	IFI6	P09912	848
IFI44L	MX1	P20591	841
IFI44L	ISG15	P05161	840
IFI44L	OAS1	P00973	806
IFI44L	OASL	Q15646	800
IFI44L	IFITM3	Q01628	757
IFI44L	SIGLEC1	Q9BZZ2	728
IFI44L	XAF1	Q6GPH4	726
IFI44L	PARP9	Q8IXQ6	723
IFI44L	LY6E	Q16553	710
IFI44L	IFI44	Q8TCB0	702

IntAct

3 interactions, top by confidence:

A	B	Type	Score
IFNA21	IFIT3	psi-mi:“MI:0914”(association)	0.530

BioGRID (15): IFI44L (Affinity Capture-MS), IFI44L (Affinity Capture-MS), BAG5 (Affinity Capture-MS), CALML5 (Affinity Capture-MS), IGKC (Affinity Capture-MS), LDHA (Affinity Capture-MS), LHX2 (Affinity Capture-MS), LYZ (Affinity Capture-MS), MDH1 (Affinity Capture-MS), PSMA1 (Affinity Capture-MS), RAB3GAP1 (Affinity Capture-MS), IFI44L (Affinity Capture-MS), RALA (Cross-Linking-MS (XL-MS)), RPL18 (Cross-Linking-MS (XL-MS)), RPL21 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A140LIF8, A0A2P1BRP3, A0A386CAB9, A0JN92, A1A4Y4, O14791, P27473, P59045, P86448, P86449, Q0GUM3, Q13075, Q3B7D9, Q3T9E4, Q3TL54, Q53G44, Q5NCI0, Q5RFJ8, Q60766, Q62293, Q66X01, Q66X03, Q66X05, Q66X22, Q6AYC2, Q6ZSC3, Q7Z745, Q84WJ0, Q86W28, Q8BV66, Q8BVM9, Q8C6J9, Q8CBA2, Q8CCN1, Q8TCB0, Q8TCY9, Q8TD90, Q90597, Q99388, Q99J64

Diamond homologs: P27473, Q53G44, Q8BV66, Q8TCB0, Q9BDB7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	7
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1407 predictions. Top by Δscore:

Variant	Effect	Δscore
1:78620568:ACAGG:A	donor_loss	1.0000
1:78620569:CAGGT:C	donor_loss	1.0000
1:78620570:AGGTA:A	donor_loss	1.0000
1:78620571:GGTAA:G	donor_loss	1.0000
1:78620572:G:C	donor_loss	1.0000
1:78628058:G:GT	donor_gain	1.0000
1:78628058:G:T	donor_gain	1.0000
1:78628996:GAGA:G	donor_gain	1.0000
1:78628998:GA:G	donor_gain	1.0000
1:78629000:G:GG	donor_gain	1.0000
1:78635335:A:AG	acceptor_gain	1.0000
1:78635336:G:GG	acceptor_gain	1.0000
1:78637031:GTTTA:G	acceptor_gain	1.0000
1:78620573:T:G	donor_loss	0.9900
1:78620876:T:TA	acceptor_gain	0.9900
1:78620892:T:A	acceptor_gain	0.9900
1:78635336:GTATA:G	acceptor_gain	0.9900
1:78635468:T:TA	donor_gain	0.9900
1:78635485:ATCAG:A	donor_loss	0.9900
1:78635486:TCAG:T	donor_loss	0.9900
1:78635487:CAG:C	donor_loss	0.9900
1:78635488:AG:A	donor_loss	0.9900
1:78635489:GGT:G	donor_loss	0.9900
1:78635490:G:GT	donor_loss	0.9900
1:78635491:T:TC	donor_loss	0.9900
1:78637030:A:AG	acceptor_gain	0.9900
1:78637031:G:GG	acceptor_gain	0.9900
1:78641092:A:G	donor_gain	0.9900
1:78641603:G:GT	donor_gain	0.9900
1:78641604:A:T	donor_gain	0.9900

AlphaMissense

3012 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:78628381:T:C	F156L	0.960
1:78628383:T:A	F156L	0.960
1:78628383:T:G	F156L	0.960
1:78629821:A:C	K210T	0.933
1:78629853:T:C	F221L	0.930
1:78629855:T:A	F221L	0.930
1:78629855:T:G	F221L	0.930
1:78629826:A:C	S212R	0.927
1:78629828:T:A	S212R	0.927
1:78629828:T:G	S212R	0.927
1:78629821:A:T	K210M	0.916
1:78629838:T:C	S216P	0.914
1:78628002:G:C	K29N	0.913
1:78628002:G:T	K29N	0.913
1:78628385:G:C	R157P	0.912
1:78629822:G:C	K210N	0.910
1:78629822:G:T	K210N	0.910
1:78628377:A:C	E154D	0.908
1:78628377:A:T	E154D	0.908
1:78628382:T:C	F156S	0.903
1:78629842:T:A	V217D	0.901
1:78629847:T:C	S219P	0.901
1:78641528:G:C	D415H	0.901
1:78629829:T:C	F213L	0.890
1:78629831:T:A	F213L	0.890
1:78629831:T:G	F213L	0.890
1:78641494:T:A	N403K	0.890
1:78641494:T:G	N403K	0.890
1:78628045:T:C	C44R	0.879
1:78628067:T:A	I51K	0.879

dbSNP variants (sampled 300 via entrez): RS1000018323 (1:78623571 G>A,C), RS1000232270 (1:78633904 A>C,G), RS1000407360 (1:78622319 C>T), RS1000476201 (1:78639857 TGCC>T), RS1000484208 (1:78623368 C>T), RS1000529006 (1:78619136 A>T), RS1000836554 (1:78642090 A>C,T), RS1000926388 (1:78644619 G>T), RS1001043317 (1:78638802 A>G,T), RS1001048343 (1:78636149 C>T), RS1001096040 (1:78632383 G>C), RS1001115639 (1:78642294 A>C,G), RS1001234829 (1:78632633 A>T), RS1001376065 (1:78621188 T>C), RS1001408597 (1:78620816 C>T)

Disease associations

OMIM: gene MIM:613975 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001877_50	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	1.000000e-06
GCST002295_4	Schizophrenia or bipolar disorder	8.000000e-09
GCST002672_5	Febrile seizures	1.000000e-09
GCST002674_1	Febrile seizures (MMR vaccine-related)	6.000000e-12
GCST004269_1	Immune response to measles vaccine (measles-specific neutralising antibody titre)	1.000000e-10
GCST004269_5	Immune response to measles vaccine (measles-specific neutralising antibody titre)	2.000000e-08
GCST006284_18	Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease	6.000000e-07
GCST008660_1	Lung function in never smokers (high FEV1 vs average FEV1)	3.000000e-07

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0006519	MMR-related febrile seizures
EFO:0004645	response to vaccine
EFO:0006899	PCSK9 protein measurement
EFO:0004314	forced expiratory volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

84 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, increases expression, decreases expression	5
sodium arsenite	affects expression, decreases expression, increases expression	4
(+)-JQ1 compound	decreases expression, increases expression	3
Air Pollutants	increases abundance, decreases expression	3
Benzo(a)pyrene	decreases expression, decreases methylation, increases expression, increases methylation	3
Cadmium Chloride	decreases expression, increases abundance	3
monomethylarsonous acid	decreases expression	2
Nickel	increases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
Valproic Acid	affects cotreatment, increases expression	2
Particulate Matter	decreases expression, decreases reaction, increases abundance	2
aristolochic acid I	decreases expression	1
testosterone enanthate	affects expression	1
bisphenol A	decreases expression	1
cinnamaldehyde	decreases expression	1
butyraldehyde	decreases expression	1
nickel chloride	increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	decreases expression	1
chloroquine diphosphate	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
cupric chloride	decreases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, decreases reaction	1
diallyl trisulfide	decreases expression	1
monomethylpropion	affects expression	1
gadodiamide	increases expression	1
azoxystrobin	increases expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1FS	Abcam A-549 IFI44L KO 1	Cancer cell line	Male
CVCL_B2NB	Abcam A-549 IFI44L KO 2	Cancer cell line	Male
CVCL_XP72	HAP1 IFI44L (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.